Cargando…

Serum Iron Level and 10-Year Survival after Melanoma

The malignant melanoma of the skin is a very aggressive tumor. The determination of prognostic biomarkers is important for the early detection of recurrence, and for the enrollment of the patients into different treatment regimens. An evaluation of a cohort of 375 Polish MM cases revealed that a low...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowińska, Karolina, Baszuk, Piotr, Rogoża-Janiszewska, Emilia, Deptuła, Jakub, Marciniak, Wojciech, Derkacz, Róża, Lener, Marcin, Cybulski, Cezary, Kiedrowicz, Magdalena, Boer, Magdalena, Marchlewicz, Mariola, Dębniak, Tadeusz, Lubiński, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775579/
https://www.ncbi.nlm.nih.gov/pubmed/36551774
http://dx.doi.org/10.3390/biomedicines10123018
_version_ 1784855679263047680
author Rowińska, Karolina
Baszuk, Piotr
Rogoża-Janiszewska, Emilia
Deptuła, Jakub
Marciniak, Wojciech
Derkacz, Róża
Lener, Marcin
Cybulski, Cezary
Kiedrowicz, Magdalena
Boer, Magdalena
Marchlewicz, Mariola
Dębniak, Tadeusz
Lubiński, Jan
author_facet Rowińska, Karolina
Baszuk, Piotr
Rogoża-Janiszewska, Emilia
Deptuła, Jakub
Marciniak, Wojciech
Derkacz, Róża
Lener, Marcin
Cybulski, Cezary
Kiedrowicz, Magdalena
Boer, Magdalena
Marchlewicz, Mariola
Dębniak, Tadeusz
Lubiński, Jan
author_sort Rowińska, Karolina
collection PubMed
description The malignant melanoma of the skin is a very aggressive tumor. The determination of prognostic biomarkers is important for the early detection of recurrence, and for the enrollment of the patients into different treatment regimens. An evaluation of a cohort of 375 Polish MM cases revealed that a low serum iron concentration (i.e., below 893.05 µg/L) was associated with increased mortality. The study group was followed up from the date of melanoma diagnosis until death or 2020. Patients were assigned to one of four categories in accordance with increasing iron level (I–IV quarters). Patients with a low iron level of below 893.05 µg/L (I quarter) had a significantly lower survival rate when compared to the subgroup with the highest iron level, above 1348.63 µg/L (IV quarter; HR = 4.12; p = 0.028 and HR = 4.66; p = 0.019 for uni- and multivariable models, respectively). Multivariable analysis took into account the following factors: iron levels, Clark, sex, and age. Future studies based upon the examination of a larger number of cases should be conducted to confirm our findings.
format Online
Article
Text
id pubmed-9775579
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97755792022-12-23 Serum Iron Level and 10-Year Survival after Melanoma Rowińska, Karolina Baszuk, Piotr Rogoża-Janiszewska, Emilia Deptuła, Jakub Marciniak, Wojciech Derkacz, Róża Lener, Marcin Cybulski, Cezary Kiedrowicz, Magdalena Boer, Magdalena Marchlewicz, Mariola Dębniak, Tadeusz Lubiński, Jan Biomedicines Brief Report The malignant melanoma of the skin is a very aggressive tumor. The determination of prognostic biomarkers is important for the early detection of recurrence, and for the enrollment of the patients into different treatment regimens. An evaluation of a cohort of 375 Polish MM cases revealed that a low serum iron concentration (i.e., below 893.05 µg/L) was associated with increased mortality. The study group was followed up from the date of melanoma diagnosis until death or 2020. Patients were assigned to one of four categories in accordance with increasing iron level (I–IV quarters). Patients with a low iron level of below 893.05 µg/L (I quarter) had a significantly lower survival rate when compared to the subgroup with the highest iron level, above 1348.63 µg/L (IV quarter; HR = 4.12; p = 0.028 and HR = 4.66; p = 0.019 for uni- and multivariable models, respectively). Multivariable analysis took into account the following factors: iron levels, Clark, sex, and age. Future studies based upon the examination of a larger number of cases should be conducted to confirm our findings. MDPI 2022-11-23 /pmc/articles/PMC9775579/ /pubmed/36551774 http://dx.doi.org/10.3390/biomedicines10123018 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Rowińska, Karolina
Baszuk, Piotr
Rogoża-Janiszewska, Emilia
Deptuła, Jakub
Marciniak, Wojciech
Derkacz, Róża
Lener, Marcin
Cybulski, Cezary
Kiedrowicz, Magdalena
Boer, Magdalena
Marchlewicz, Mariola
Dębniak, Tadeusz
Lubiński, Jan
Serum Iron Level and 10-Year Survival after Melanoma
title Serum Iron Level and 10-Year Survival after Melanoma
title_full Serum Iron Level and 10-Year Survival after Melanoma
title_fullStr Serum Iron Level and 10-Year Survival after Melanoma
title_full_unstemmed Serum Iron Level and 10-Year Survival after Melanoma
title_short Serum Iron Level and 10-Year Survival after Melanoma
title_sort serum iron level and 10-year survival after melanoma
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775579/
https://www.ncbi.nlm.nih.gov/pubmed/36551774
http://dx.doi.org/10.3390/biomedicines10123018
work_keys_str_mv AT rowinskakarolina serumironleveland10yearsurvivalaftermelanoma
AT baszukpiotr serumironleveland10yearsurvivalaftermelanoma
AT rogozajaniszewskaemilia serumironleveland10yearsurvivalaftermelanoma
AT deptułajakub serumironleveland10yearsurvivalaftermelanoma
AT marciniakwojciech serumironleveland10yearsurvivalaftermelanoma
AT derkaczroza serumironleveland10yearsurvivalaftermelanoma
AT lenermarcin serumironleveland10yearsurvivalaftermelanoma
AT cybulskicezary serumironleveland10yearsurvivalaftermelanoma
AT kiedrowiczmagdalena serumironleveland10yearsurvivalaftermelanoma
AT boermagdalena serumironleveland10yearsurvivalaftermelanoma
AT marchlewiczmariola serumironleveland10yearsurvivalaftermelanoma
AT debniaktadeusz serumironleveland10yearsurvivalaftermelanoma
AT lubinskijan serumironleveland10yearsurvivalaftermelanoma